Xilio Therapeutics, Inc. Increase (Decrease) in Accounts Receivable
Xilio Therapeutics, Inc. (XLO) reported Increase (Decrease) in Accounts Receivable of $1.00 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccountsReceivable · last filed 2026-08-12
- Xilio Therapeutics, Inc. increase (decrease) in accounts receivable for the quarter ending 2026-06-30 was $6.00M.
- Xilio Therapeutics, Inc. increase (decrease) in accounts receivable for the quarter ending 2026-03-31 was -$5.00M.
- Xilio Therapeutics, Inc. increase (decrease) in accounts receivable for the quarter ending 2025-12-31 was -$12.50M.
- Xilio Therapeutics, Inc. increase (decrease) in accounts receivable for the quarter ending 2025-03-31 was $0.00, a 100.00% decline year-over-year.
- Xilio Therapeutics, Inc. increase (decrease) in accounts receivable for fiscal 2025 was $5.00M.
| Period end | Increase (Decrease) in Accounts Receivable 3 month | Increase (Decrease) in Accounts Receivable 6 month | Increase (Decrease) in Accounts Receivable 9 month | Increase (Decrease) in Accounts Receivable 12 month |
|---|---|---|---|---|
| 2026-06-30 | $6.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | $1.00M 10-Q · filed 2026-08-12 | -$11.50M derived: sum of 3 quarters · filed 2026-08-12 | |
| 2026-03-31 | -$5.00M 10-Q · filed 2026-05-12 | -$17.50M derived: sum of 2 quarters · filed 2026-05-12 | ||
| 2025-12-31 | -$12.50M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-23 | $5.00M 10-K · filed 2026-03-23 | ||
| 2025-09-30 | $17.50M 10-Q · filed 2025-11-13 | |||
| 2025-03-31 | $0.00 10-Q · filed 2026-05-12 | |||
| 2024-03-31 | $30.00M 10-Q · filed 2025-05-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Serina Therapeutics, Inc. (SER) | United States | $0.054B | -2.35 |
| Clene Inc. (CLNN) | United States | $0.054B | -1.99 |
| HERON THERAPEUTICS, INC. /DE/ (HRTX) | United States | $0.055B | -2.38 |
| Elicio Therapeutics, Inc. (ELTX) | United States | $0.049B | |
| Lite Strategy, Inc. (LITS) | United States | $0.049B | |
| Dogwood Therapeutics, Inc. (DWTX) | United States | $0.049B | |
| Annovis Bio, Inc. (ANVS) | United States | $0.056B | -1.58 |
| Werewolf Therapeutics, Inc. (HOWL) | United States | $0.047B | |
| NOMAD POWER SOLUTIONS, INC. (NMAD) | United States | $0.058B | |
| Grace Therapeutics, Inc. (GRCE) | $0.046B | -1.83 |